Prelude Therapeutics Incorporated (PRLD)

USD 0.91

(2.18%)

Market Cap (In USD)

49.87 Million

Revenue (In USD)

-

Net Income (In USD)

-121.83 Million

Avg. Volume

273.61 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.797-6.8
PE
-
EPS
-
Beta Value
1.546
ISIN
US74065P1012
CUSIP
74065P101
CIK
1678660
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Krishna Vaddi D.V.M., Ph.D.
Employee Count
-
Website
https://www.preludetx.com
Ipo Date
2020-09-25
Details
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.